Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 10/20 | 0.66 |
| ▸ | MMP2 | P08253 | 1/20 | 0.66 |
| ▸ | MMP9 | P14780 | 1/20 | 0.66 |
| ▸ | MMP8 | P22894 | 1/20 | 0.66 |
| ▸ | MMP13 | P45452 | 1/20 | 0.66 |
| ▸ | SULT1A1 | P50225 | 4/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | SNCA | P37840 | 1/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628260 | 0.88 | APP (0.73) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL1996999 | 0.88 | APP (0.73) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL17086888 | 0.84 | APP (0.65) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL2628255 | 0.84 | APP (0.63) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL2633250 | 0.84 | KDM4E (0.68) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL5423269 | 0.83 | APP (0.81) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL2464396 | 0.83 | APP (0.66) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL21043886 | 0.83 | APP (0.66) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL2461783 | 0.83 | APP (0.66) | APPMMP2MMP9MMP8MMP13 | |
| SCHEMBL10311768 | 0.83 | RORC (0.71) | APPMMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9134328-B2 | Methods of using benzothiazole derivative compounds and compositions | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-09-15 | — | — | US | disclosed |
| US-9134328-B2 | Methods of using benzothiazole derivative compounds and compositions | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140220590-A1 | METHODS OF USING BENZOTHIAZOLE DERIVATIVE COMPOUNDS AND COMPOSITIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140220590-A1 | METHODS OF USING BENZOTHIAZOLE DERIVATIVE COMPOUNDS AND COMPOSITIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-08-07 | — | — | US | disclosed |
| US-8580229-B2 | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580229-B2 | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580229-B2 | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-11-12 | — | — | US | disclosed |
| EP-1771208-B1 | USE OF THIOFLAVIN RADIOLABELED DERIVATIVES IN AMYLOID IMAGING FOR ASSESSING ANTI-AMYLOID THERAPIES | UNIV PITTSBURGH (US) | 2013-06-19 | — | — | EP | disclosed |
| EP-1771208-B1 | USE OF THIOFLAVIN RADIOLABELED DERIVATIVES IN AMYLOID IMAGING FOR ASSESSING ANTI-AMYLOID THERAPIES | UNIV PITTSBURGH (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130045164-A1 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-02-21 | — | — | US | disclosed |
| EP-1768709-A1 | A METHOD OF DIAGNOSING PRODROMAL FORMS OF DISEASES ASSOCIATED WITH AMYLOID DEPOSITION | University of Pittsburgh (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2007035405-A2 | IN-VIVO AND IN-VITRO METHOD FOR DETECTING AMYLOID DEPOSITS HAVING AT LEAST ONE AMYLOIDOGENIC PROTEIN | UNIVERSITY OF PITTSBURGH (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035405-A2 | IN-VIVO AND IN-VITRO METHOD FOR DETECTING AMYLOID DEPOSITS HAVING AT LEAST ONE AMYLOIDOGENIC PROTEIN | UNIVERSITY OF PITTSBURGH (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| WO-2006014381-A9 | USE OF THIOFLAVIN RADIOLABELED DERIVATIVES IN AMYLOID IMAGING GOR ASSESSING ANTI-AMYLOID THERAPIES | UNIV PITTSBURGH (US) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006014381-A2 | USE OF THIOFLAVIN RADIOLABELED DERIVATIVES IN AMYLOID IMAGING GOR ASSESSING ANTI-AMYLOID THERAPIES | UNIVERSITY OF PITTSBURGH (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006014382-A1 | A METHOD OF DIAGNOSING PRODROMAL FORMS OF DISEASES ASSOCIATED WITH AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1611115-A1 | BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES | University of Pittsburgh (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004083195-A1 | BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES | UNIVERSITY OF PITTSBURGH (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045164-A1 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES | TTR, APP, SAAL1 | APP 2/4885MMP2 2277/4885MMP9 3907/4885 |
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | APP 1/4885MMP2 3126/4885MMP9 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.